Is the business good?
How good a business is PAHC?
Phibro Animal Health Corporation earns 16% on the capital it employs against a 9.0% cost of capital, so the business is worth more the bigger it gets.
16%
Return on invested capital · cost of capital 9.0% · 6.7 points above what the capital costs: growth creates value
- Operating margin
- 12%
Operating margin · Drug Manufacturers - Specialty & Generic median 12% · 12 months to Q3 2026
- Cash conversion
- 0.13×
Cash conversion · 1.54× a year ago · some of the reported profit has not turned into cash yet
- Share count, year on year
- +0.81%
Share count, year on year · flat: no meaningful dilution
| Year | Operating margin |
|---|---|
| FY2020 | 8.6% |
| FY2021 | 9.0% |
| FY2022 | 8.4% |
| FY2023 | 7.3% |
| FY2024 | 5.2% |
| FY2025 | 8.5% |
Details›
- Gross margin12 months to Q3 2026
- 33%
- Operating margin12 months to Q3 2026
- 12%
- Net margin12 months to Q3 2026
- 6.3%
- Free cash flow margin
- 0.85%
- Revenue, trailing twelve months
- $1.50B
- Free cash flow, trailing twelve months
- $13M
- Net income, trailing twelve months
- $95M
- Return on invested capitaloperating profit after tax ÷ debt + equity − cash
- 16%
Margins, capital and share counts from the statements as filed with the SEC; cash conversion from the cash flow statement.
Drug Manufacturers - Specialty & Generic
Ranks #11 of 28 by Smart Score